<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly</h1>
  <ul>
<li>Sep 15 - Novo Nordisk (NYSE:NVO) reported that a higher semaglutide dose helped patients lose more weight in two late-stage trials, and its Copenhagen-listed shares rose about 1.5%.</li>
<li>The trials tested a 7.2 mg dose, three times the approved 2.4 mg, and measured weight change over 72 weeks.</li>
<li>Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top dose, keeping competition tight.Observers said the incremental gains for semaglutide matter, esp</li>
<li>This article first appeared on GuruFocus.</li>
<li>In the larger study, participants on 7.2 mg lost an average of 19 percent of body weight, compared with about 16 percent on 2.4 mg and 4 percent on placebo.</li>
<li>Novo has faced setbacks in the U.S., including market share losses and a roughly 60 percent share decline over the past year as it trims its global workforce.</li>
<li>The data may strengthen Novo's case for higher-dose strategies if regulators and payers accept the approach.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/novo-nordisk-shares-rise-obesity-124422607.html">Source</a> · 2025-09-15T12:44:22+00:00</p>
</body>
</html>